electroCore, Inc. Announces Exclusive Distribution Agreement With Byond Healthcare Pty Ltd, South Africa
electroCore, Inc. Announces Exclusive Distribution Agreement With Byond Healthcare Pty Ltd, South Africa. electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, announced an agreement with Byond Healthcare Pty Ltd. to serve as the exclusive distributor of gammaCore SapphireTM, non-invasive vagus nerve stimulator (nVNS) in South Africa and Namibia.
“Access to exceptional medical technologies is key to improving healthcare outcomes,” said David Loubser, Managing Director of Byond Healthcare Pty Ltd. “It is a privilege for Byond to provide clinicians in South Africa and Namibia with a cutting-edge, clinically proven tool that we believe can help combat the opioid crisis by treating a variety of pain conditions with a non-pharmaceutical therapeutic option. Cleared by reputable authorities such as the U.S. FDA, TGA, Health Canada, and EU, gammaCore is a practical solution that aligns with Byond’s focus on making innovative pain management technologies accessible to both patients and healthcare providers. As a first-line treatment option for primary headache-related pain, gammaCore is a perfect fit for Byond’s mission.”
“We are excited to be working with Byond in expanding accessibility of our nVNS technology for headache sufferers in South Africa and Namibia,” said Iain Strickland, SVP, Global Sales and Strategy at electroCore. “Byond’s focus on innovative pain management solutions makes them an ideal distributor for us as we take gammaCore into Africa nations for the first time. This agreement helps us to mobilize the response to calls from patients and clinicians alike to make gammaCore available in South Africa and Namibia.”
The initial term of the agreement is three years and contains customary terms and conditions, and regulatory clearances are required before sales and revenue can occur.
